ArticleThe Prostate2018

2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.

Emmanuel S Akinboye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.